114 related articles for article (PubMed ID: 35093840)
1. Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications - A pilot study.
Moser T; Otto F; O'Sullivan C; Hitzl W; Pilz G; Harrer A; Trinka E; Wipfler P
Mult Scler Relat Disord; 2022 Mar; 59():103560. PubMed ID: 35093840
[TBL] [Abstract][Full Text] [Related]
2. Humoral and cellular responses to repeated COVID-19 exposure in multiple sclerosis patients receiving B-cell depleting therapies: a single-center, one-year, prospective study.
Alfonso-Dunn R; Lin J; Lei J; Liu J; Roche M; De Oliveira A; Raisingani A; Kumar A; Kirschner V; Feuer G; Malin M; Sadiq SA
Front Immunol; 2023; 14():1194671. PubMed ID: 37449202
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Observation of SARS-CoV-2 Vaccination Response upon High Efficacy Treatment in Multiple Sclerosis-A Real-World Scenario.
Schraad M; Runkel S; Hitzler W; Protopapa M; Bittner S; Uphaus T; Zipp F
Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543930
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose.
Di Filippo M; Ferraro D; Ragonese P; Prosperini L; Maniscalco GT; Gallo A; Cavalla P; Lorefice L; Nociti V; Di Sabatino E; Clerico M; Guaschino C; Radaelli M; Fantozzi R; Buttari F; Laroni A; Gajofatto A; Calabrese M; Malucchi S; Paolicelli D; De Luca G; Tomassini V; Lanzillo R; Moccia M; Solaro C; Cocco E; Gasperini C; Tortorella C;
J Neurol; 2024 Jan; 271(1):24-31. PubMed ID: 37922069
[TBL] [Abstract][Full Text] [Related]
5. Prior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccination.
Asashima H; Kim D; Wang K; Lele N; Buitrago-Pocasangre NC; Lutz R; Cruz I; Raddassi K; Ruff WE; Racke MK; Wilson JE; Givens TS; Grifoni A; Weiskopf D; Sette A; Kleinstein SH; Montgomery RR; Shaw AC; Li F; Fan R; Hafler DA; Tomayko MM; Longbrake EE
JCI Insight; 2023 Aug; 8(16):. PubMed ID: 37606046
[TBL] [Abstract][Full Text] [Related]
6. Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL.
Campanella A; Capasso A; Heltai S; Taccetti C; Albi E; Herishanu Y; Haggenburg S; Chatzikonstantinou T; Doubek M; Kättström M; Giannopoulos K; Simkovic M; Moreno C; Massaia M; Bumbea H; Alshemmari S; Ranghetti P; Perotta E; Martini F; Sant'Antonio E; Colia M; Combi C; Levi S; Kater AP; Hazenberg M; Nijhof IS; Hofsink Q; Demosthenous C; Kotaskova J; Zaleska J; Vrbacky F; Raya AM; Bisogno D; Tripoli IE; Popov VM; Roman V; Stavroyianni N; Karypidou M; Scarano E; Locatelli M; Frenquelli M; Scarfò L; Stamatopoulos K; Ghia P
Am J Hematol; 2024 Apr; 99(4):745-750. PubMed ID: 38264829
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 Vaccine-Elicited Immunity after B Cell Depletion in Multiple Sclerosis.
Baxter RM; Cabrera-Martinez B; Ghosh T; Rester C; Moreno MG; Borko TL; Selva S; Fleischer CL; Haakonsen N; Mayher A; Bowhay E; Evans C; Miller TM; Huey L; McWilliams J; van Bokhoven A; Deane KD; Knight V; Jordan KR; Ghosh D; Klarquist J; Kedl RM; Piquet AL; Hsieh EWY
Immunohorizons; 2024 Mar; 8(3):254-268. PubMed ID: 38483384
[TBL] [Abstract][Full Text] [Related]
8. Analysis of vaccine responses after anti-CD20 maintenance in B-cell lymphoma in the Balearic Islands. A single reference center experience.
Gutierrez A; Alonso A; Garcia-Recio M; Perez S; Garcia-Maño L; Martinez-Serra J; Ros T; Garcia-Gasalla M; Ferrer J; Vögler O; Alemany R; Salar A; Sampol A; Bento L
Front Immunol; 2023; 14():1267485. PubMed ID: 38022668
[TBL] [Abstract][Full Text] [Related]
9. Breakthrough COVID-19 in people with multiple sclerosis on disease modifying treatments: Is it still a severe disease?
Immovilli P; Schiavetti I; Franceschini A; De Mitri P; Gelati L; Rota E; Guidetti D
Mult Scler Relat Disord; 2024 May; 85():105547. PubMed ID: 38518506
[TBL] [Abstract][Full Text] [Related]
10. IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients.
Xie H; Zhang J; Luo R; Qi Y; Lin Y; Han C; Li X; Zeng D
BMC Immunol; 2024 Jan; 25(1):5. PubMed ID: 38218761
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod.
van Kempen ZL; van Dam KP; Keijser JB; Stalman EW; Kummer LY; Strijbis EM; Steenhuis M; Ten Brinke A; van Ham SM; Kuijpers T; Rispens T; Eftimov F; Wieske L; Killestein J
Mult Scler; 2024 Mar; 30(3):443-447. PubMed ID: 37942812
[TBL] [Abstract][Full Text] [Related]
12. B Cell Reconstitution is Associated With COVID-19 Booster Vaccine Responsiveness in Patients Previously Seronegative Treated With Rituximab.
Schultz K; Jannat-Khah D; Spiera R
J Rheumatol; 2023 Mar; 50(3):420-425. PubMed ID: 36521910
[TBL] [Abstract][Full Text] [Related]
13. Immune features revealed by single-cell RNA and single-cell TCR/BCR sequencing in patients with rheumatoid arthritis receiving COVID-19 booster vaccination.
Fan Y; Huang S; Wu D; Chu M; Zhao J; Zhang J; Wang Y; Gui Y; Ye X; Wang G; Geng Y; Wang Y; Zhang Z
J Med Virol; 2024 Apr; 96(4):e29573. PubMed ID: 38566569
[TBL] [Abstract][Full Text] [Related]
14. Response to SARS-CoV-2 initial series and additional dose vaccine in pediatric patients with predominantly antibody deficiency.
Tandon M; DiGiacomo DV; Zhou B; Hesterberg P; Rosenberg CE; Barmettler S; Farmer JR
Front Immunol; 2023; 14():1217718. PubMed ID: 37575247
[TBL] [Abstract][Full Text] [Related]
15. Effects of Influenza Vaccine on the Immune Responses to SARS-CoV-2 Vaccination.
Riccomi A; Trombetta CM; Dorrucci M; Di Placido D; Sanarico N; Farchi F; Giuseppetti R; Villano U; Marcantonio C; Marchi S; Ciaramella A; Pezzotti P; Montomoli E; Valdarchi C; Ciccaglione AR; Vendetti S
Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675807
[TBL] [Abstract][Full Text] [Related]
16. Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL.
Tomasulo E; Paul S; Mu R; Tian X; Chen J; Pleyer C; Wiestner A; Sun C
Leuk Lymphoma; 2023 Dec; 64(14):2306-2315. PubMed ID: 37732614
[TBL] [Abstract][Full Text] [Related]
17. Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies.
Chung DJ; Shah GL; Devlin SM; Ramanathan LV; Doddi S; Pessin MS; Hoover E; Marcello LT; Young JC; Boutemine SR; Serrano E; Sharan S; Momotaj S; Margetich L; Bravo CD; Papanicolaou GA; Kamboj M; Mato AR; Roeker LE; Hultcrantz M; Mailankody S; Lesokhin AM; Vardhana SA; Knorr DA
Blood Cancer Discov; 2021 Nov; 2(6):568-576. PubMed ID: 34778797
[TBL] [Abstract][Full Text] [Related]
18. Ensitrelvir eradicates persistent SARS-CoV-2 infection in a follicular lymphoma patient treated with anti-CD20 antibodies.
Sakamaki I; Negoro E; Iwasaki H; Yamauchi T
J Infect Chemother; 2024 Feb; 30(2):147-149. PubMed ID: 37690521
[TBL] [Abstract][Full Text] [Related]
19. Sequential cellular and humoral responses after repetitive COVID-19 vaccination in patients treated with anti-CD20 antibodies.
Nishikubo M; Shimomura Y; Yamamoto R; Maruoka H; Nasu S; Sakizono K; Nagai Y; Hiramoto N; Yonetani N; Kondo T; Miyakoshi C; Doi A; Ishikawa T
Br J Haematol; 2024 Mar; 204(3):821-825. PubMed ID: 37964419
[TBL] [Abstract][Full Text] [Related]
20. Polypharmacy and Antibody Response to SARS-CoV-2 Vaccination in Residents of Long-Term Care Facilities: The GeroCovid Vax Study.
Trevisan C; Haxhiaj L; Malara A; Abbatecola A; Fedele G; Palmieri A; Leone P; Schiavoni I; Stefanelli P; Maggi S; Sergi G; Volpato S; Incalzi RA; Onder G;
Drugs Aging; 2023 Dec; 40(12):1133-1141. PubMed ID: 37938521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
